AmeriFlex Group’s Recursion Pharmaceuticals RXRX Stock Holding History

AmeriFlex Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.14K	Hold	2,000	–	–	﹤0.01%	802
2025 Q4	$8.18K	Buy	2,000 +1,876	+1,513%	+$9.29K	﹤0.01%	750
2025 Q3	$605	Buy	124 +62	+100%	+$326	﹤0.01%	1025
2025 Q2	$335	Sell	62 -2,000	-97%	-$9.82K	﹤0.01%	1030
2025 Q1	$10.9K	Buy	2,062 +2,000	+3,226%	+$14.6K	﹤0.01%	827
2024 Q4	$449	Buy	+62	New	+$417	﹤0.01%	1127

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AmeriFlex Group's RXRX Position: Q1 2026 in Review

AmeriFlex Group held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 2,000 shares worth $6.14K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

AmeriFlex Group first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.9K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

AmeriFlex Group held 2,000 shares of Recursion Pharmaceuticals worth $6.14K as of Q1 2026.
AmeriFlex Group left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of AmeriFlex Group's portfolio in Q1 2026, its #802 holding.
AmeriFlex Group first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
AmeriFlex Group's Recursion Pharmaceuticals position peaked at $10.9K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on AmeriFlex Group's 13F filing for Q1 2026, filed 15 May 2026.